The Clinical Sample Acquisition and Repository Scientific Research Support Component (SRSC) will provide human clinical samples required for the studies outlined in the CHAVI-ID research plan. One key goal of CHAVI-ID is to study subjects that make broad neutralizing antibodies (BnAbs) in order to understand how best to induce BnABs. Another key goal is to receive vaccine trial samples from collaborating networks and to provide these samples to CHAVI-ID investigators. The clinical samples that are needed for the B, T and Innate cell studies as well as studies in the SRSCs, are those from chronically infected subjects who have been extensively characterized for their ability to make broad neutralizing antibodies (BnAbs), and samples from HIV-1 vaccine trials carried out by the HIV Vaccine Trials Network (HVTN), the Military HIV Research Program (MHRP) or the NIH Vaccine Research Center (VRC) as well as control samples. It is also important to have a sample repository comprised of both samples from control groups, samples from volunteers in vaccine trials as well as samples from both acute and chronic HIV-1 infection cohorts, such that when opportunities arise to test new hypotheses that require clinical material, CHAVI-ID research can move quickly ahead without stopping to write and get new clinical protocols approved.
Specific Aims Aim 1. To recruit and maintain the CHAVI-ID clinical sites for CHAVI-ID studies.
Aim 2. To maintain high quality specimen processing laboratories at the CHAVI-ID sites to ensure the highest quality sample acquisition.
Aim 3. To maintain CHAVI-ID repository sample storage facilities for distribution to CHAVI-ID investigators.

Public Health Relevance

Access to HIV-infected patients followed over time is essential to understanding the immunology of HlV-1 infection. Having experienced and skilled clinical research personnel is essential for obtaining and maintaining high quality clinical specimens to support the research that can lead to successful vaccine design.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI100645-03
Application #
8681343
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
3
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
City
Durham
State
NC
Country
United States
Zip Code
27705
Prévost, Jérémie; Richard, Jonathan; Medjahed, Halima et al. (2018) Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses. J Virol 92:
Prévost, Jérémie; Richard, Jonathan; Ding, Shilei et al. (2018) Envelope glycoproteins sampling states 2/3 are susceptible to ADCC by sera from HIV-1-infected individuals. Virology 515:38-45
Saunders, Kevin O; Santra, Sampa; Parks, Robert et al. (2018) Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. J Virol 92:
Wu, Helen L; Wiseman, Roger W; Hughes, Colette M et al. (2018) The Role of MHC-E in T Cell Immunity Is Conserved among Humans, Rhesus Macaques, and Cynomolgus Macaques. J Immunol 200:49-60
Wiehe, Kevin; Bradley, Todd; Meyerhoff, R Ryan et al. (2018) Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. Cell Host Microbe 23:759-765.e6
Cheng, Hao D; Grimm, Sebastian K; Gilman, Morgan Sa et al. (2018) Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. JCI Insight 3:
Castillo-Menendez, Luis R; Witt, Kristen; Espy, Nicole et al. (2018) Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers. J Virol 92:
Brown, Eric P; Weiner, Joshua A; Lin, Shu et al. (2018) Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1/SIV. J Immunol Methods 455:24-33
Finney, Joel; Yeh, Chen-Hao; Kelsoe, Garnett et al. (2018) Germinal center responses to complex antigens. Immunol Rev 284:42-50
Pardi, Norbert; Hogan, Michael J; Naradikian, Martin S et al. (2018) Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med 215:1571-1588

Showing the most recent 10 out of 261 publications